Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: β-cell


Diabetes: Concepts of β-Cell Organ Dysfunction and Failure Would Lead to Earlier Diagnoses and Prevention

October 28th 2021

There is a potential to identify both T2D and T1D at stages well before the onset of currently recognized clinical disease (Diabetes)

Categories: Genetics, News, Screening
Tags: Type 1 Diabetes, Type 2 Diabetes, β-cell

Categories: Genetics, Screening
Tags: Type 1 Diabetes, Type 2 Diabetes, β-cell

Probing β-Cell Biology in Space and Time

September 30th 2021

Scientists must be able to investigate (and visualize) short- and long-lived events within the pancreas and β-cells. Current technological advances in microscopy are able to bridge multiple spatiotemporal scales in biology to reveal the complexity and heterogeneity of β-cell biolog (Diabetes)

Categories: News, Pathology
Tags: β-cell

Categories: Pathology
Tags: β-cell

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

July 14th 2021

A 26-week course of imatinib preserved β-cell function at 12 months in adults with recent-onset type 1 diabetes. Imatinib might offer a novel means to alter the course of type 1 diabetes (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: imatinib, Type 1 Diabetes, β-cell

Categories: Medication
Tags: imatinib, Type 1 Diabetes, β-cell

Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone

April 7th 2021

Glycemia is strongly associated with β-cell dysfunction in adults with early T2DM treated with metformin alone. Efforts to improve glycemia should focus on interventions aimed at improving β-cell function (Journal of Diabetes and Its Complications)

Categories: News, Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Categories: Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

March 2nd 2021

The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile (The Lancet Diabetes & Endocrinology)

Categories: News, Treatment
Tags: liraglutide, Type 1 Diabetes, β-cell

Categories: Treatment
Tags: liraglutide, Type 1 Diabetes, β-cell

Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia

February 4th 2021

β Cell function can persist in long-duration T1DM. With a peak C-peptide concentration of >0.03 nmol/L, we observed clinically meaningful reductions in the prevalence of severe hypoglycemia (Journal of Clinical Investigation)

Categories: News, Pathology
Tags: hypoglycemia, Type 1 Diabetes, β-cell

Categories: Pathology
Tags: hypoglycemia, Type 1 Diabetes, β-cell

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

October 21st 2018

In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes (Journal of Diabetes Research)

Categories: News, Treatment
Tags: insulin, Type 2 Diabetes, β-cell

Categories: Treatment
Tags: insulin, Type 2 Diabetes, β-cell

Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes

February 6th 2018

The findings indicate that outpatient clinic-based IIT to ensure euglycaemia in newly diagnosed patients with T2DM might be an effective initial therapeutic option for improvements in β-cell function and glycaemic control over the long term, without serious adverse events (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: Type 2 Diabetes, β-cell

Categories: Treatment
Tags: Type 2 Diabetes, β-cell

Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes

September 4th 2016

There is evidence of ongoing autoimmunity in the majority of individuals with longstanding diabetes. Endogenous insulin secretion continues for many years after diagnosis in individuals diagnosed with autoimmune-mediated type 1 diabetes above age 5. These findings suggest that some beta cells are protected from continued autoimmune attack in longstanding type 1 diabetes (Diabetologia)

Categories: News, Pathology
Tags: autoimmunity, Type 1 Diabetes, β-cell

Categories: Pathology
Tags: autoimmunity, Type 1 Diabetes, β-cell

β-Cell death is decreased in women with gestational diabetes mellitus

August 25th 2016

These results demonstrate that β-cell death is reduced in women with GDM. This reduction is associated with impaired insulin production and hyperglycemia, suggesting that β-cell death does not contribute to GDM during the 2nd and 3rd trimester of pregnancy (Diabetology & Metabolic Syndrome)

Categories: Gestational, News
Tags: β-cell

Categories: Gestational
Tags: β-cell

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes

August 25th 2016

Compared with GLAR, EXE improved the parameters of β-cell function, especially insulin secretion at 8 mmol/L glucose and β-cell glucose sensitivity, which was sustained during the 3-year treatment period (EJE)

Categories: Medication, News
Tags: Type 2 Diabetes, β-cell

Categories: Medication
Tags: Type 2 Diabetes, β-cell

β-cell dysfunction in women with previous gestational diabetes is associated with visceral adipose tissue distribution

May 7th 2015

Women with GDM are at increased risk of developing pre-diabetes and have a decreased β-cell function 5 years post-partum that is associated with increased visceral fat mass (European Journal of Endocrinology)

Categories: Gestational, News
Tags: visceral, β-cell

Categories: Gestational
Tags: visceral, β-cell

Lipotoxic Stress Induces Pancreatic β-Cell Apoptosis through Modulation of Bcl-2 Proteins by the Ubiquitin-Proteasome System

May 6th 2015

Our results suggest that targeting the UPS and Bcl-2 protein expression may be a valuable strategy to prevent β-cell demise in type 2 diabetes (Journal of Diabetes Research)

Categories: News, Treatment
Tags: Apoptosis, Type 2 Diabetes, β-cell

Categories: Treatment
Tags: Apoptosis, Type 2 Diabetes, β-cell

Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to Roux-en-Y gastric bypass

April 22nd 2015

Both weight loss and preserved β-cell function predominantly determine greatest glycemic benefit after RYGB (Diabetes)

Categories: Bariatric, News
Tags: RYGB, β-cell

Categories: Bariatric
Tags: RYGB, β-cell

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaBoehringer IngelheimNapp DiabetesNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership